摘要
目的:建立艾迪注射液超适应证用药标准,为临床合理使用该药提供参考。方法:(1)建立标准:分析2016年某院艾迪注射液使用情况和主要适应证,制定检索策略,检索The Cochrane Library、Pubmed、ELSEVIER、CNKI等数据库,运用GRADE profiler 3.6软件对系统评价进行分析,运用RevMan 5.3软件对随机对照试验(RCT)进行meta分析,对超适应证用药进行循证评价并建立标准。(2)依据该标准对抽取病历进行点评,提出问题并进行整改,比较干预前后效果。结果:文献检索后纳入10篇系统评价,4篇RCT。艾迪注射液联合某些化疗方案可用于胃癌、结直肠癌,不建议用于食管癌等疾病。依据以上标准干预我院艾迪注射液用药,取得了良好效果。结论:基于循证医学方法建立艾迪注射液超适应证用药标准切实可行。
OBJECTIVE To establish the criteria of Aidi injection for off-label use and provide a reference for rational clinical use of the drug. METHODS(1) Establishment of criteria: We analyzed the use and main indications of Aidi injection in a hospital in 2016 and then formulated search strategy. Databases including the Cochrane Library, Pubmed, ELSEVIER, CNKI and other databases were searched. GRADE profiler 3.6 software was used to analyze the systematic review and RevMan 5.3 software was used to perform a meta-analysis of randomized controlled trials(RCTs). Evidence-based appraisal was conducted for off-label and the criteria was established.(2) The medical records were reviewed by the established criteria and concerned questions were raised and rectification were made. Effects before and after intervention were compared. RESULTS Ten systematic reviews and four RCTs were included after the literature search. Aidi injection combined with certain chemotherapy regimens can be used for gastric cancer, colorectal cancer, and is not recommended for diseases such as esophageal cancer. According to the above criterias, we intervened in the use of Aidi injection in our hospital and achieved good results. CONCLUSION It is feasible to establish evaluation standards for off-label use of aidi injection by applying evidence-based medicine method.
引文
[1] Shi Q, Diao Y, Jin F,et al. Anti-metastatic effects of aidi on human esophageal squamous cell carcinoma by inhibiting epithelial-mesenchymal transition and angiogenesis[J]. Mol Med Rep, 2018, 18(1): 131-138.
[2] Zhang WZ, Du J. Short-term and long-term therapeutic effects of addie injection in treatment of advanced lung cancer[J]. Chin Hospital Pharm J(中国医院药学杂志), 2015, 35(20): 1865-1869.
[3] Liu F, Ma R, Liao X,et al. Traditional chinese medicine injection clinical use management model for evaluation[J]. China J Chin Mater Med(中国中药杂志), 2012, 37(18): 2752-2755.
[4] Jin R, Wang YG, Xue CM,et al. Exploration on criteria and compromise of prescription review of chinese patent medicines IV: inappropriate indications for drug use[J]. Chin Hosp Pharm J(中国医院药学杂志), 2015, 35(13): 1161-1167.
[5] Sun H, Shi JP. Expansion of PICO model in evidence-based medicine and its application in qualitative research[J].Chin J Evid Base Med(中国循证医学杂志), 2014, 14(5): 505-508.
[6] Zeng XT, Sun Z, Tang HM. Meta-analysis series X: establishment of eligibility criteria[J]. Chin J Evid Based Cardiovasc Med(中国循证心血管医学杂志), 2013, 5(1): 6-9.
[7] Xiong J, Cheng RX. An introduction to a measurement tool to assess the methodological quality of systematic reviews/meta-analysis: AMSTAR[J]. Chin J Evid Base Med(中国循证医学杂志), 2011, 11(9): 1084-1089.
[8] Shea BJ, Grimshaw JM, Wells GA,et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews[J]. BMC Med Res Methodol, 2007, 7(1): 1-7.
[9] Ma XH, Kang J, Zhang XJ, et al. Establishment of evidence-based criteria to evaluate the new rational use of thymalfasin[J]. Chin Hosp Pharm J(中国医院药学杂志), 2017, 37(3): 273-277.
[10] Zhang HY, Wang HL, Shi YF,et al. Efficacy and safety of TCM prescription for gout versus allopurinol in the treatment of gout: a systematic review[J]. J China Pharm(中国药房), 2018,(3): 401-405.
[11] Zhang D, Zheng J, Ni M,et al. Comparative efficacy and safety of Chinese herbal injections combined with the FOLFOX regimen for treating gastric cancer in China: a network meta-analysis[J]. Oncotarget, 2017, 8(40): 68873-68889.
[12] Chi ZH, Yu S, Cui M. Meta-analysis of aidi injection combined with S-1 for advanced gastric cancer[J]. J China Pharm(中国药房), 2017, 28(33): 4675-4678.
[13] Wang JC, Ge L, Zhao Y, et al. Effect of aidi injection plus chemotherapy on gastric carcinoma: a meta-analysis of randomized controlled trials[J]. J Tradit Chin Med, 2015, 35(4): 361-374.
[14] Li R, Ning H, Liu Y,et al. Aidi combined with chemotherapy for gastric carcinoma:a systematic review[J]. J China Pharm(中国药房), 2011,(40): 3813-3817.
[15] Ge L, Mao L, Tian JH,et al. Network meta-analysis on selecting Chinese medical injections in radiotherapy for esophageal cancer[J]. China J Chin Mater Med(中国中药杂志), 2015, 40(18): 3674-3681.
[16] Zhang D, Wu JR, Liu S, et al. Meta-analysis on the randomized controlled trials of aidi injection treating for colorectal cancer[J]. J Pharmacoepidemiol(药物流行病学杂志), 2017, 26(12): 796-802.
[17] Ge L, Wang YF, Tian JH, et al. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer[J]. J Clin Pharm Ther, 2016, 41(4): 383-391.
[18] Li DQ, Lin FY. Aidi injection combined with chemotherapy for middle-advanced colorectal cancer: a meta-analysis[J]. Strait Pharm J(海峡药学), 2016, 28(12): 113-116.
[19] Ji B, Yuan J. Meta-analysis of the clinical efficacy and safety about aidi injection in the treatment of colorectal cancer[J]. J China Pharm(中国药房), 2011,22(40): 3797-3799.
[20] Zhang D, Wu J, Liu S, et al. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer[J]. Medicine, 2017, 96(21): e7005.
[21] Dai QG. Clinical evaluation of aidi injection combined with chemotherapy in the treatment of 72 patients with advanced head and neck neoplasms[J]. Guide Chin Med(中国医药指南), 2013,(24): 137-138.
[22] Wang FQ, Liu YC. Observation on aidi injection and CAG plan in treating 40 cases of senile acute myelocytic leukemia[J]. West J Chin Tradit Med(西部中医药), 2012, 25(12): 85-87.
[23] Li DH, Yang JY, Lu L. The therapeutic action of aidi injection for the function of toxicity reducing and efficacy enhancing and disordered intestinal flora after the chemotherapy to the acute leukemia patients[J]. Chin J Microecol, 2007, 19(4): 345-346.s
[24] Guo LS, Chai T, Liu YC, et al. Clinical observation of aidi injection combined with chemotherapy in treatment of acute leukemia[J]. Chin J Pract Chin Mod Med(中华实用中西医杂志), 2005, 18(3): 343-344.
[25] Jin R, Zhao KJ, Guo GM,et al. Expert consensus on prescription comment of chinese traditional patent medicine for promoting the rational use of drugs in Beijing[J]. China J Chin Mater Med(中国中药杂志), 2018, 43(5): 1049-1053.
[26] Zhang W, Wang L, Zhao YL,et al. Assessment of off-label use of alprostadil injection by evidence-based medical approach[J]. Chin Hosp Pharm J(中国医院药学杂志), 2017, 37(2): 177-180.
[27] Atkins D, Best D, Briss PA,et al. Grading quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7653):1106-1110.
[28] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650): 924-926.
[29] Schünemann HJ, Oxman AD, Brozek J,et al. Rating quality of evidence and strength of recommendations: GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies[J]. BMJ, 2008, 336(7653): 1106.
[30] Schunemann HJ, Oxman D, Vist GE,et al. GRADE guidelines:3. rating the quality of evidence[J]. Chin J Evid Base Med(中国循证医学杂志), 2011, 11(4): 451-455.
[31] Zhao HY, Li GH, Qi ZY, et al. Efficacy and safety of aidi injection combined with paclitaxed and cisplatin in the treatment of advanced non-small cell lung cancer:a meta-analysis[J]. J China Pharm(中国药房), 2016: 27(9): 1210-1213.
